A rapid communication released by the World Health Organization (WHO) Global Tuberculosis Programme has announced upcoming updates to the guidance on the treatment of drug-resistant tuberculosis (DR-TB). These updates include shorter novel 6-month all-oral regimens for the treatment of multidrug- and rifampicin-resistant TB (MDR/RR-TB), with or without additional resistance to fluoroquinolones (pre-XDR-TB) as well as an alternative 9-month all-oral regimen for the treatment of MDR/RR-TB. Read Here.
top of page
Recent Posts
See AllThe Indonesia AIDS Coalition (IAC) and Indonesia for Global Justice (IGJ) have filed a patent opposition for the Tuberculosis (TB) drug Bedaquiline with dispersible tablet formulations (hereinafter, i
350
Calls for strengthening health systems in preparation for the next pandemic have intensified in the wake of COVID-19, with estimates ranging from $15 billion to $50 billion needed annually to scale up
540
The monitoring and evaluation framework of the TB Action Plan for the WHO European Region 2023–2030 includes four new indicators reflecting consistent meaningful engagement of the communities and civi
540
bottom of page